New insulin candidate shows promise in large diabetes trial
NCT ID NCT05834868
First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested a new insulin called THDB0206 against a commonly used insulin (lispro) in over 1000 Chinese adults with type 2 diabetes. Both insulins were taken alongside a long-acting insulin (glargine). The goal was to see how well each controlled blood sugar over 26 weeks. This is a disease management study, not a cure, as participants will need ongoing insulin therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhongshan Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.